Innovations in Calcified Carotid Lesion Preparation for Enhanced Stroke Management

By João L. Carapinha

June 26, 2026

calcified carotid lesion preparation

Johnson & Johnson has begun enrolling patients in the SKYWARD clinical program, advancing calcified carotid lesion preparation with a purpose-built intravascular lithotripsy platform that fractures hardened plaque to improve stent deployment. This first-of-its-kind carotid IVL system addresses a critical gap in care for patients whose dense arterial calcium makes both surgery and conventional endovascular procedures more hazardous.

Innovative Dual-Access Trial Framework

Two prospective, multicenter, single-arm IDE studies are evaluating the carotid IVL catheter via transcarotid and transfemoral access routes ahead of commercially available stents. Up to 185 participants per pathway, including roll-in cases, will be followed for five years across as many as 50 U.S. centers under the guidance of leading vascular surgeons and interventionalists.

Overcoming Barriers in Calcified Carotid Lesion Preparation

Calcified carotid lesion preparation remains especially challenging when heavy plaque burdens narrow cerebral blood flow and raise complication rates for carotid endarterectomy or stenting. The new rapid-exchange, anatomically optimized IVL catheter directly responds to physician-identified needs, enhancing arterial compliance and enabling more predictable stent apposition where traditional techniques frequently fall short.

Evidence Generation for Future Neurovascular Strategies

Extended five-year outcomes from these high-risk cohorts will supply robust longitudinal data to quantify stroke-risk reduction and economic value. By delivering targeted innovation in calcified carotid lesion preparation, the SKYWARD program lays essential groundwork for expanded endovascular options and informed policy conversations surrounding novel neurovascular technologies.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
KEYTRUDA combination therapy
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer

By João L. Carapinha

June 26, 2026

The FDA has approved KEYTRUDA combination therapy with Trodelvy as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 at a Combined Positive Score of 10 or greater. This marks the first regulatory nod for a PD-...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...